حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
BEXIMCO PHARMA.GDR REGS 1
R2WABeximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh. Address: 19 Dhanmondi R/A, Dhaka, Bangladesh, 1205
Analytics
سعر الهدف في وول ستريت
–نسبة السعر إلى الأرباح
3.71العائد الربحي
7.93 %السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
الشخصيات الرئيسية R2WA
تحليلات الأرباح R2WA
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–نمو الأرباح على مدى 5 سنوات
109.00 %النمو المستمر
1 سنةمعدل الدفع 5 سنوات في المتوسط
–تاريخ الأرباح R2WA
تقييم الأسهم R2WA
المالية R2WA
نتائج | 2019 | ديناميات |